0001185185-20-001327.txt : 20200915 0001185185-20-001327.hdr.sgml : 20200915 20200915145750 ACCESSION NUMBER: 0001185185-20-001327 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 19 CONFORMED PERIOD OF REPORT: 20200914 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20200915 DATE AS OF CHANGE: 20200915 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BioSig Technologies, Inc. CENTRAL INDEX KEY: 0001530766 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] IRS NUMBER: 264333375 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38659 FILM NUMBER: 201175821 BUSINESS ADDRESS: STREET 1: 54 WILTON ROAD, 2ND FLOOR CITY: WESTPORT STATE: CT ZIP: 06880 BUSINESS PHONE: (203) 409-5444 MAIL ADDRESS: STREET 1: 54 WILTON ROAD, 2ND FLOOR CITY: WESTPORT STATE: CT ZIP: 06880 8-K 1 biosig20200914_8k.htm FORM 8-K biosig20200914_8k.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C.  20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): September 14, 2020

 

BioSig Technologies, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware

001-38659

26-4333375

(State or other jurisdiction

(Commission File Number)

(IRS Employer

of incorporation)

  

Identification No.)

 

54 Wilton Road, 2nd Floor

Westport, Connecticut

  

06880

(Address of principal executive offices)

  

(Zip Code)

 

(203) 409-5444

(Registrant’s telephone number, including area code)

 

                                       N/A                                        

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐ Pre-commencement communications pursuant to Rule 13e-4 (c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading Symbol(s)

 

Name of exchange on which registered

Common Stock, par value $0.001 per share

 

BSGM

 

The NASDAQ Capital Market  

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 
 

 

Item 7.01             Regulation FD Disclosure.

 

On September 14, 2020, BioSig Technologies, Inc. (the “Company”) issued a press release, attached hereto as Exhibit 99.1, announcing that the Company will host a call and webcast to discuss the results from the first randomized, blinded signal sample analysis in the PURE EP 2.0 Clinical Study on Tuesday, September 15, 2020 at 11:00 AM Eastern Time. Also on September 14, 2020, the Company issued a press release announcing that the Company’s abstract for ‘Computational Reconstruction of Electrocardiogram Lead Placement’ was accepted for presentation at the 2020 Computing in Cardiology Conference (CinC). The Company undertakes no obligation to update, supplement or amend the materials attached hereto as Exhibit 99.1 and Exhibit 99.2.

 

On September 15, 2020, the Company issued a press release, attached hereto as Exhibit 99.3, announcing that a scientific abstract and poster, titled “A novel cardiac signal processing system for electrophysiology procedures: early insights from the PURE EP 2.0 study,” is available electronically from August 30, 2020 at the ESC Congress 2020 – The Digital Experience. The Company undertakes no obligation to update, supplement or amend the materials attached hereto as Exhibit 99.3.

 

In accordance with General Instruction B.2 of Form 8-K, the information in this Item 7.01 of this Current Report on Form 8-K, including Exhibits 99.1, 99.2 and 99.3, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, except as shall be expressly set forth by reference in such a filing. Furthermore, the furnishing of information under Item 7.01 of this Current Report on Form 8-K is not intended to constitute a determination by the Company that the information contained herein, including the exhibits hereto, is material or that the dissemination of such information is required by Regulation FD.

 

Item 9.01             Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit Number

 

Description

99.1

 

Press Release, dated September 14, 2020

99.2

  

Press Release, dated September 14, 2020

99.3

  

Press Release, dated September 15, 2020

104

 

Cover Page Interactive Data File (formatted as Inline XBRL)

 

 

 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

 

 

 

 

 

Date: September 15, 2020    

By:

/s/ Kenneth L. Londoner 

 

 

 

Name: Kenneth L. Londoner

 

 

 

Title: Executive Chairman

 

 

 

 

 
NASDAQ false 0001530766 0001530766 2020-09-14 2020-09-14
EX-99.1 2 ex_203709.htm EXHIBIT 99.1 ex_203709.htm

 

Exhibit 99.1

 

 

 

Reminder: BioSig to Host Conference Call and Webcast on September 15, 2020 to Discuss Unblinding of PURE EP Human Data

 

Westport, CT, Sept. 14, 2020 (GLOBE NEWSWIRE) --

 

 

●

Peer-reviewed, blinded, randomized data recently presented at ESC Congress 2020
 

●

Commercial market update discussion
 

●

Presentation to include webcast

 

Westport, CT, September 14, 2020 — BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”), a medical technology company developing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced it will host a call and webcast to discuss the results from the first randomized, blinded signal sample analysis in the PURE EP 2.0 Clinical Study. The data was generated during atrial fibrillation ablation procedures conducted at St. David’s Medical Center, Austin, Texas.

 

Conference Call Details:

Date: Tuesday, September 15, 2020 Time: 11:00 AM Eastern Time (ET)

Dial in Number for U.S. Callers: 1-877-407-8293

Webcast link: https://event.webcasts.com/starthere.jsp?ei=1369137&tp_key=cbdbc3a4b8

 

A replay will be available for two weeks starting on September 15, 2020, at approximately 3:00 PM ET. To access the replay, please dial 877-660-6853 in the U.S. The conference ID# is 13709732.

 

On August 04, 2020, BioSig announced that the Company installed its PURE EP(tm) System at Massachusetts General Hospital (MGH) as part of an expanding clinical study. “The PURE EP(tm) System evaluation and data collection at MGH will commence under the leadership of investigator Moussa Mansour M.D., Director of MGH’s Cardiac Electrophysiology Laboratory and Atrial Fibrillation Program.”

 

About BioSig Technologies

BioSig Technologies is a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals (www.biosig.com).

 

The Company’s first product, PURE EP(tm) System is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording and storing of electrocardiographic and intracardiac signals for patients undergoing electrophysiology (EP) procedures in an EP laboratory.

 

Forward-looking Statements

This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward- looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) the geographic, social and economic impact of COVID-19 on our ability to conduct our business and raise capital in the future when needed, (ii) our inability to manufacture our products and product candidates on a commercial scale on our own, or in collaboration with third parties; (iii) difficulties in obtaining financing on commercially reasonable terms; (iv) changes in the size and nature of our competition; (v) loss of one or more key executives or scientists; and (vi) difficulties in securing regulatory approval to market our products and product candidates. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

 

Andrew Ballou

BioSig Technologies, Inc.

Vice President, Investor Relations

54 Wilton Road, 2nd floor

Westport, CT 06880

aballou@biosigtech.com

203-409-5444, x133

 

 

 

 
 EX-99.2 3 ex_203854.htm EXHIBIT 99.2 ex_203854.htm

 

Exhibit 99.2

 

 

BioSig Announces Abstract Acceptance to Computing in Cardiology 2020

 

Westport, CT, Sept. 14, 2020 (GLOBE NEWSWIRE) --

 

 

●

Novel algorithm can successfully reconstruct ECG lead placements
 

●

The method may improve the automated classification of patient conditions and unlock new applications of clinical value

 

BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that the Company’s abstract for ‘Computational Reconstruction of Electrocardiogram Lead Placement’ was accepted for presentation at the 2020 Computing in Cardiology Conference (CinC).

 

The abstract was co-authored by Dr. Alexander D. Wissner-Gross of Reified LLC, Dr. Suraj Kapa of the Mayo Clinic, James Lee, Natasha Drapeau, and Kenneth L. Londoner of BioSig Technologies, Inc. The manuscript presents a method for computationally reconstructing the spatial placement of electrocardiogram (ECG) leads using only correlations between their recorded signals and without requiring external calibration or other prior knowledge. The work further examines the association of various cardiac abnormalities with the reconstructed geometries and reviews potential clinical applications of the method.

 

“We are encouraged by the early successes that Alex and his team have demonstrated in developing machine learning solutions for PURE EP(tm). From early disease detection to more accurate diagnosis to improved decision making during treatment, the transformative potential of artificial intelligence and machine learning in healthcare is vast. We are excited to report on our progress during the CinC 2020 and look forward to exploring further clinical applications through novel AI-powered algorithms,” commented Kenneth L. Londoner, Chairman and CEO of BioSig Technologies, Inc.

 

“We found that electrophysiological waveforms could encode a surprising amount of spatial information about the context in which they were recorded and look forward to translating this and other advanced biomedical signal analytics into clinical usage,” added Dr. Wissner- Gross.

 

CinC 2020 takes place on September 13-16, 2020, in a hybrid of live and online sessions, in Rimini, Italy. The Company’s abstract will be presented virtually by Dr. Alexander D. Wissner-Gross, on Tuesday, September 15, from 15:45-17:45 Central European Time (09:45 – 11:45 Eastern Time).

 

Please view the CinC 2020 program using this link.

 

In December 2019, the Company announced that it partnered with Cambridge, Massachusetts-based Reified LLC, a provider of advanced artificial intelligence-focused technical advisory services to the private sector. Initial machine learning and AI solutions developed under the terms of this collaboration are focused on BioSig’s core competencies in electrophysiology.

 

About Computing in Cardiology

CinC provides a forum for scientists and professionals from the fields of medicine, physics, engineering, and computer science to discuss their current research on topics about computing in cardiology and cardiovascular physiology.

 

About BioSig Technologies

BioSig Technologies is a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals (www.biosig.com).

 

The Company’s first product, PURE EP (tm) System is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording and storing of electrocardiographic and intracardiac signals for patients undergoing electrophysiology (EP) procedures in an EP laboratory.

 

 
 

 

Forward-looking Statements

 

This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward- looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) the geographic, social and economic impact of COVID-19 on our ability to conduct our business and raise capital in the future when needed, (ii) our inability to manufacture our products and product candidates on a commercial scale on our own, or in collaboration with third parties; (iii) difficulties in obtaining financing on commercially reasonable terms; (iv) changes in the size and nature of our competition; (v) loss of one or more key executives or scientists; and (vi) difficulties in securing regulatory approval to market our products and product candidates. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

 

Andrew Ballou

BioSig Technologies, Inc.

Vice President, Investor Relations

54 Wilton Road, 2nd floor

Westport, CT 06880

aballou@biosigtech.com

203-409-5444, x133

 

 

 
 EX-99.3 4 ex_203855.htm EXHIBIT 99.3 ex_203855.htm

 

Exhibit 99.3

 

 

BioSig Releases PURE EP Study Abstract with Data Presented at European Society of Cardiology’s ‘ESC Congress 2020’

 

Positive responses confirm that the PURE EP signals are preferred to conventional sources of intracardiac signals in a blinded, independent analysis. Abstract concludes PURE EP™ System is able to produce reliable and high-quality signals when compared to the available standard of care systems.

 

Westport, CT, Sept. 15, 2020 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) ("BioSig" or the "Company"), a medical technology company developing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced a scientific abstract and poster entitled, "A novel cardiac signal processing system for electrophysiology procedures: early insights from the PURE EP 2.0 study" is available electronically from August 30th at the ESC Congress 2020 – The Digital Experience.

 

The abstract is co-authored by Carola Gianni, M.D., Amin Al-Ahmad, M.D., Shane M. Bailey, M.D., G. Joseph Gallinghouse, M.D., Rodney P. Horton, M.D. and Andrea Natale, M.D. of the Texas Cardiac Arrhythmia Institute (TCAI) at St. David’s Medical Center in Austin, TX. The independent, blinded reviewers were Bradley P. Knight, M.D. (Northwestern University), Wendy Tzou, M.D. (University of Colorado), and Pasquale Santangeli, M.D. (University of Pennsylvania).

 

Identical electrocardiographic and intracardiac signal data were recorded during 15 atrial fibrillation ablation procedures from the PURE EP™ System, the signal recording system, and the 3D mapping system. The collected signals underwent blinded, controlled evaluation by three independent electrophysiologists to determine whether the PURE EP™ signals are a viable alternative to conventional sources and if it provides additional or clearer diagnostic information. Reviewers were asked to record the quality of each signal sample on a scale of 1-10 and select a rationale for their rating in a dropdown menu.

 

Based on the ratings for each pair of signals, a cumulative total of 29 PURE EP™ signals out of 34 (85.3%) were rated as statistically equivalent or better for this dataset. In 35.5% of samples, the reviewers selected PURE EP™ data because "more signal components were visible." The abstract concludes that the PURE EP™ System is able to produce reliable and high-quality signals when compared to the available standard of care systems.

 

“BioSig Technologies is very pleased to see some of the early results from the PURE EP™ study shared during ESC 2020. We greatly appreciate the scientific collaboration with the team at TCAI and the independent EP reviewers. The PURE EP™ study is on-going, and we look forward to sharing multi-center data with the EP community in the coming months," commented Julie Stephenson, VP of Clinical Affairs at BioSig Technologies, Inc.

 

Exceptionally, this year, the online event is available at no charge, but pre-registration is required: Register for the ESC Congress 2020 – The Digital Experience

 

About ESC Congress 2020

The European Society of Cardiology (ESC) is an independent, non-profit organization. Its members and decision-makers are busy healthcare professionals who volunteer their time and expertise. The ESC represents more than 95,000 men and women in the field of cardiology from Europe, the Mediterranean Basin, and far beyond. Due to the COVID-19 pandemic, the government in the Netherlands has banned all meetings until September 1. As Amsterdam was to be the host city, it is no longer possible for ESC Congress to take place as planned. However, the ESC remains committed to delivering practice-changing science to the cardiology community and looks forward to bringing you 'ESC Congress 2020 - The Digital Experience'.

 

About BioSig Technologies

BioSig Technologies is a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals (www.biosig.com).

 

The Company's first product, PURE EP (tm) System is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording and storing of electrocardiographic and intracardiac signals for patients undergoing electrophysiology (EP) procedures in an EP laboratory.

 

 
 

 

Forward-looking Statements

 

This press release contains "forward-looking statements." Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Forward- looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) the geographic, social and economic impact of COVID-19 on our ability to conduct our business and raise capital in the future when needed, (ii) our inability to manufacture our products and product candidates on a commercial scale on our own, or in collaboration with third parties; (iii) difficulties in obtaining financing on commercially reasonable terms; (iv) changes in the size and nature of our competition; (v) loss of one or more key executives or scientists; and (vi) difficulties in securing regulatory approval to market our products and product candidates. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

 

Andrew Ballou

BioSig Technologies, Inc.

Vice President, Investor Relations

54 Wilton Road, 2nd floor

Westport, CT 06880

aballou@biosigtech.com

203-409-5444, x133

 

 

 
 EX-101.SCH 5 bsgm-20200914.xsd XBRL TAXONOMY EXTENSION SCHEMA 000 - Document - Document And Entity Information link:presentationLink link:definitionLink link:calculationLink EX-101.DEF 6 bsgm-20200914_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 7 bsgm-20200914_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE EX-101.PRE 8 bsgm-20200914_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 9 ex_203709img001.jpg begin 644 ex_203709img001.jpg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end GRAPHIC 10 ex_203854img001.jpg begin 644 ex_203854img001.jpg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end GRAPHIC 11 ex_203855img001.jpg begin 644 ex_203855img001.jpg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end XML 12 biosig20200914_8k_htm.xml IDEA: XBRL DOCUMENT 0001530766 2020-09-14 2020-09-14 8-K 2020-09-14 BioSig Technologies, Inc. DE 001-38659 26-4333375 54 Wilton Road, 2nd Floor Westport CT 06880 (203) 409-5444 false false false false Common Stock, par value $0.001 per share BSGM false NASDAQ false 0001530766 XML 13 R1.htm IDEA: XBRL DOCUMENT v3.20.2
Document And Entity Information
Sep. 14, 2020
Document Information Line Items  
Entity Registrant Name BioSig Technologies, Inc.
Trading Symbol BSGM
Document Type 8-K
Amendment Flag false
Entity Central Index Key 0001530766
Document Period End Date Sep. 14, 2020
Entity Emerging Growth Company false
Entity Incorporation, State or Country Code DE
Entity File Number 001-38659
Entity Tax Identification Number 26-4333375
Entity Address, Address Line One 54 Wilton Road, 2nd Floor
Entity Address, City or Town Westport
Entity Address, State or Province CT
Entity Address, Postal Zip Code 06880
City Area Code (203)
Local Phone Number 409-5444
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.001 per share
Security Exchange Name NASDAQ
EXCEL 14 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( #AW+U$'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " X=R]12&;<*_ K @ $0 &1O8U!R;W!S+V-O&ULS9+/ M3L,P#(=?!>7>.NTV)J*N%Q GD)"8!.(6)=X6K?FCQ*C=VY.6K1."!^ 8^Y?/ MGR4W*@CE([Y$'S"2P70SV,XEH<*&'8B" $CJ@%:F,B=<;NY\M)+R,^XA2'64 M>X2:\UNP2%)+DC "BS 36=MH)51$23Z>\5K-^/ 9NPFF%6"'%ATEJ,H*6#M. M#*>A:^ *&&&$T:;O NJ9.%7_Q$X=8.?DD,R&PO M=&AE;64O=&AE;64Q+GAM;.U:6W/:.!1^[Z_0>&?V;0O&-H&VM!-S:7;;M)F$ M[4X?A1%8C6QY9)&$?[]'-A#+E@WMDDVZFSP$+.G[SD5'Y^@X>?/N+F+HAHB4 M\GA@V2_;UKNW+][@5S(D$4$P&:>O\, *I4Q>M5II ,,X?+&A T%116F]?(+3E'S/X%/F7/Z3H=,H%N,!M8('_.;Z?D3EJ(X53"Q,!J9S]6 M:\?1TDB @LE]E 6Z2?:CTQ4(,@T[.IU8SG9\]L3MGXS*VG0T;1K@X_%X.+;+ MTHMP' 3@4;N>PIWT;+^D00FTHVG09-CVVJZ1IJJ-4T_3]WW?ZYMHG J-6T_3 M:W?=TXZ)QJW0> V^\4^'PZZ)QJO0=.MI)B?]KFNDZ19H0D;CZWH2%;7E0-,@ M %AP=M;,T@.67BGZ=90:V1V[W4%<\%CN.8D1_L;%!-9ITAF6-$9RG9 %#@ W MQ-%,4'RO0;:*X,*2TER0UL\IM5 :")K(@?5'@B'%W*_]]9>[R:0S>IU].LYK ME']IJP&G[;N;SY/\<^CDGZ>3UTU"SG"\+ GQ^R-;88C'(CN]WV6'WV3T=N(]>IP+,BUY1&)$6? MR"VZY!$XM4D-,A,_")V&F&I0' *D"3&6H8;XM,:L$> 3?;>^",C?C8CWJV^: M/5>A6$G:A/@01AKBG'/F<]%L^P>E1M'V5;SCFED)O816:I^JAS0^J!XR"@7QN1X^Y7IX"C>6QKQ0KH)[ ?_1VC?"J_B" MP#E_+GW/I>^Y]#VATK\>WZV22$KYI9+2,6D$N!LT$DN/R+RO JQ GH9%LE"0AMNZ5/U2I77Y:^Y*+@\6^3IKZ%T/BS/^3Q?Y[3-"S-#MW)+ZK:4OK4F M.$KTL@'37[]EUVY".E,%.70[@:0KX#;;J=W#HXGIB1 MN0K34I!OP_GIQ7@:XCG9!+E]F%=MY]C1T?OGP5&PH^\\EAW'B/*B(>ZAAIC/ MPT.'>7M?F&>5QE T%&ULK"0L1K=@N-?Q+!3@9& MH >#KU$"\E)58#%;Q@,K MD*)\3(Q%Z'#GEUQ?X]&2X]NF9;5NKREW&6TB4CG":9@39ZO*WF6QP54=SU5; M\K"^:CVT%4[/_EFMR)\,$4X6"Q)(8Y07IDJB\QE3ON>;G*YZ(G;Z MEW?!8/+]<,E'#^4[YU_T74.N?O;=X_INDSM(3)QYQ1$!=$4"(Y4U#VT%SU&\Z.9X!ZSAW.;>KC"1:S_6-8>^3+?.7#;.MX# M7N83+$.D?L%]BHJ $:MBOKJO3_DEG#NT>_&!()O\UMND]MW@#'S4JUJE9"L1 M/TL'?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO M0=5 Y3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$% M @ .'5%HN:)+FO'[L8[_'[G@CU;-. Q[S=)<7_828XJOCJ.C!#*N MSV0!.7ZSDBKC!F_5VM&% AY705GJ^*X[=#(N\MYD7#V;J\E8EB85. C=Z[9K8K2RF?[B?;J M-FW@_O6[^FW5>>S,DFN8R?1)Q":Y[(UZ+(85+U/S*#>_P:Y# ZL7R517_]EF M^VX0]%A4:B.S73 29"+??O+7W4#L!W@' OQ=@%]Q;QNJ**^YX9.QDANF[-NH M9B^JKE;1""=RFY70*/Q68)R97,NHQ$$V;)K'["8WPKRQNWR;;1RUL6.P$?NJ M$^T$K[:"_@'!$(HSY@4GS'=]]]_A#K+5@'X-Z%=Z_2[ /2KV U]B=P8R3;30 MKUOH5RT$!UK8]?H1UD(;Q;&I!YY!6\]IG2LA0[%F"XB27*9R+4"?('5T1C & M-6- :B\4CT6^9N%;MI1I&QL=?Q5^NR XKSG.CYDW,R11/,5,Q_#*OL-;&Q&MY+JN M-^B[Y\,A@36JL4;'Y6@.2DB[J&.&UM":+EKI?2G_\NE3QV*^J-DNCAFRFPS4 MVD[G;QAO$C:36<'SUH&C];I2Z;F-#;K'D.%RE:J0JK*9$Q8:'#@F%1*6F&5, MMHQ;![)#_?J&@MSS:N\8R%N1 GLHLR6H5A9:!.?::7\T'%Q02(T[>_XQ2 O^ MRNYBG'5B):*M1Q. M*0_/ WZ^'<^H @;=_>.LO=I'"O0Z,B[BVT-^9FWIY.6 M' 3L2:0&._DH>8RE#I?8;2JEHH ;J_=HK_X(/+-W. <7CVFY)] &9[2A MV!K_]V@'_\A6+Y"YDB\BC]I'D]:<+2BTIBIXM*U_1)M+;="6_Q+%X55+*[K# MT8AR/:^I%!YM\%4*I[AK/HQ""WSVW?X7"J6I#AYMZC]DA*,R3V1.>@@M$K@7 MIX,@""BBIB9XM(D_*6$,Y+8*9&6^LP_=2O7_JH'?5 .?]NM0IB(2QI:H>YS@ M2O#6/5>'2B=/8_P^[=ES!:<1#@_@"MONOW +!(K]7*W:\]>AUTFVMSNGS?H_ M9'=:ETC6"4C+=@(V]N_37KT0!JNE7#'/_[S\PD*(2IQOK7N-#B4[/]'R0R.C MYQ-6<,5>>%H"^]4]PYK*"NRN3K@BL9LBX-.N_<[);EZCA.=K.'@HZ1!ZF(;7 MT]_;F)R]4Z,]@=]SNRG3+(45*KEGYVC;:GNHW=X8650'R:4T>"RM+A/@F&;[ M GZ_DM*\W]BS:?W3PN0?4$L#!!0 ( #AW+U&#J:4#U $ #(& - M>&PO+] M*V-!^TQCG.+HH6M9;QWPN@^#E&3IZ73/%!>:%ID>U(/"GE1FT)C3$V5%UAB] M,Z]I)'PI5T N7.;T Y>B=&*NY4K(*=)I("HCC2/HK4!.D\#TSS&=1!1<+CI* M:.,"R6*'^%LNY3\E5M1[**3<#*8T$D5F.2(X_>#!7#R3+U)DB<^3]0Y;QZ"V-@E=J2*3T 0[3K1=^**Q+"01C?)!+7AK-)\]K".6P,M6 M(.53V,*OS97VV)"X%Q_KL TD3'4-O:$EC#(1!/VC6M0^R-[]D2RQXF+P_>!G MHV?\;3 (CPX:,OZ[Z]R"!L?ET;0_^O_R*O^.8[;< MGL,5O;J@&TO"0YC3+^%]E;L'4@Y"HM +ZD1=@WYQ3[T\\M(_X%?ZOKZ&A@\2 MSULRIWO\&6HQJ#=;U6-8EZ5JCS^%]RBYGQON_Q+%#U!+ P04 " X=R]1 MEXJ[', 3 @ "P %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">, ?0(8@S M9?$6!/D!5J(/V!(%BD6=OZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]$%)I6M6X M 4BV)8]ISI%"KM0L'C6'TD!$VV-#L%HL/D N&6:WO606IW.D5XA-/E_G;@2=&A(E@6FD7) MTZ(=I7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0 M ( #AW+U$ZJJ+G0 $ #P" / >&PO=V]R:V)O;VLN>&ULC5%=:\,P M#/PKQC]@20SH\0RVT+E6 MJ:'3"T4\4V#C-E4DYPH]&09;B(S5'WC3B?PT9>H1-N6'$2&%GN5"6&-,W&_T M_$8T'D&6A^[ ](2.(2X-PW.D0XMAU]&(B^S"1I_#6(<0Y_$_,5)=8P5+J@X> M @\Y1G"=P) :;)-6P7@H]+BB[H-5CX$E)+4* Y7L=D[E],H.KEGD7F08YRB# MN+*#\%&MA1H#V#:;7-Y-;2>C@W(-@[^&5C!W-CQ]W]P-0 M2P,$% @ .'FZ*M ^ $ !H !X;"]?+7_OR4Z?:!1W;J"V\R1&:P;*9,OL[P"D6[2*+L[C,$]J%ZSB688& MO-*]:A"2*+I!V#-DGNZ9HIP\_D-T==UI?#C]LCCP#S"\7>BI160I2A4:Y$S" M:+8VP5+BRTR6HJ@R&8HJEG!:(.+)(&UI5GVP3TZTYWD7-_=%KLWC":[?#'!X M=/X!4$L#!!0 ( #AW+U%ED'F2&0$ ,\# 3 6T-O;G1E;G1?5'EP M97-=+GAM;*V334[#,!"%KQ)E6R4N+%B@IAM@"UUP 6-/&JO^DV=:TMLS3MI* MH!(5A4VL>-Z\SYZ7K-Z/$;#HG?78E!U1?!0"50=.8ATB>*ZT(3E)_)JV(DJU MDUL0]\OE@U#!$WBJ*'N4Z]4SM')OJ7CI>1M-\$V9P&)9/(W"S&I*&:,U2A+7 MQ<'K'Y3J1*BY<]!@9R(N6%"*JX1<^1UPZGL[0$I&0[&1B5ZE8Y7HK4 Z6L!Z MVN+*&4/;&@4ZJ+WCEAIC JFQ R!GZ]%T,4TFGC",S[O9_,%F"LC*30H1.;$$ M?\>=(\G=560C2&2FKW@ALO7L^T%.6X.^D&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0 ( #AW+U'T M)Y#-100 &80 8 " @0\( !X;"]W;W)K&PO&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4 " X M=R]199!YDAD! #/ P $P @ '$$0 6T-O;G1E;G1?5'EP =97-=+GAM;%!+!08 "0 ) #X" .$P ! end XML 15 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 16 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 17 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.2 html 1 95 1 false 0 0 false 0 false false R1.htm 000 - Document - Document And Entity Information Sheet http://www.biosig.com/role/DocumentAndEntityInformation Document And Entity Information Cover 1 false false All Reports Book All Reports biosig20200914_8k.htm bsgm-20200914.xsd bsgm-20200914_def.xml bsgm-20200914_lab.xml bsgm-20200914_pre.xml ex_203709.htm ex_203854.htm ex_203855.htm http://xbrl.sec.gov/dei/2019-01-31 true false JSON 20 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "biosig20200914_8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "definitionLink": { "local": [ "bsgm-20200914_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "biosig20200914_8k.htm" ] }, "labelLink": { "local": [ "bsgm-20200914_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "bsgm-20200914_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "bsgm-20200914.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 25, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 3, "total": 3 }, "keyCustom": 0, "keyStandard": 95, "memberCustom": 0, "memberStandard": 0, "nsprefix": "bsgm", "nsuri": "http://www.biosig.com/20200914", "report": { "R1": { "firstAnchor": { "ancestors": [ "b", "span", "p", "body", "html" ], "baseRef": "biosig20200914_8k.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000 - Document - Document And Entity Information", "role": "http://www.biosig.com/role/DocumentAndEntityInformation", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "b", "span", "p", "body", "html" ], "baseRef": "biosig20200914_8k.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "bsgm_DocumentAndEntityInformationAbstract": { "auth_ref": [], "localname": "DocumentAndEntityInformationAbstract", "nsuri": "http://www.biosig.com/20200914", "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.biosig.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.biosig.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.biosig.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.biosig.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.biosig.com/role/DocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.biosig.com/role/DocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.biosig.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.biosig.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.biosig.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.biosig.com/role/DocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.biosig.com/role/DocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.biosig.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.biosig.com/role/DocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.biosig.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.biosig.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.biosig.com/role/DocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.biosig.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.biosig.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.biosig.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.biosig.com/role/DocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.biosig.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.biosig.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.biosig.com/role/DocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.biosig.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 21 0001185185-20-001327-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001185185-20-001327-xbrl.zip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�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end